Physician profile
George G Head
NPI 1063487379
$479.06
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $36.92 · 2021: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $224.08 | 2019-2021 | |
| Amgen INC. | $147.22 | 2019 | |
| Celgene Corporation | $29.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.73 | 2019 | |
| Pfizer INC. | $12.99 | 2019 | |
| Lilly USA, LLC | $12.77 | 2019 | |
| Merck Sharp & Dohme LLC | $11.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.60 | 2020 | |
| Allergan, INC. | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.